SRRK - Scholar Rock Holding Corporation

Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the 2026 Jefferies Global Healthcare Conference in New York, NY on Wednesday, June 3, 2026 at 11:40 a.m.

May 20, 2026 04:00 AM • businesswire.com

Three Biotechs That Are Top Takeover Targets

Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to talk about, and the reasons are obvious: Mounjaro revenue jumped 125% to $8.66 billion last quarter, the company raised full-year revenue guidance to $82 to $85 billion, and the market cap now sits at roughly $881.8 billion.

May 18, 2026 09:55 AM • 247wallst.com

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 38,481 shares of its common stock to six newly hired employees, consisting of inducement stock options to purchase an aggregate of 12,061 shares of common stock and inducement restricted stock units, covering an aggregate of 26,420 shares of its common stock. The awards are subject to all terms and conditions and other provision.

May 15, 2026 12:15 PM • businesswire.com

Scholar Rock Holding Corporation (SRRK) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Scholar Rock Holding Corporation (SRRK) Presents at Bank of America Global Healthcare Conference 2026 Transcript

May 12, 2026 10:20 AM • seekingalpha.com

Scholar Rock Q1 Earnings Call Highlights

Scholar Rock NASDAQ: SRRK said the U.S. Food and Drug Administration has accepted for review its resubmitted Biologics License Application for apitegromab, the company's investigational treatment for children and adults with spinal muscular atrophy, and set a PDUFA action date of Sept. 30, 2026.

May 08, 2026 06:06 PM • marketbeat.com

Scholar Rock Holding Corporation (SRRK) Q1 2026 Earnings Call Transcript

Scholar Rock Holding Corporation (SRRK) Q1 2026 Earnings Call Transcript

May 07, 2026 11:01 AM • seekingalpha.com

Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today reported financial results for the first quarter ended March 31, 2026, and provided an update on recent company developments. “With the FDA's acc.

May 07, 2026 03:00 AM • businesswire.com

Scholar Rock to Present at the BofA Securities 2026 Health Care Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the BofA Securities 2026 Health Care Conference in Las Vegas, NV, on May 12, 2026 at 8:00 a.m. PT / 11:.

Apr 29, 2026 04:00 AM • businesswire.com

Scholar Rock (NASDAQ:SRRK) COO Keith Woods Sells 10,220 Shares

Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) COO Keith Woods sold 10,220 shares of the business's stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $49.57, for a total value of $506,605.40. Following the completion of the transaction, the chief operating officer directly owned 620,055

Apr 21, 2026 01:02 AM • defenseworld.net

Scholar Rock (NASDAQ:SRRK) CFO Vikas Sinha Sells 10,410 Shares of Stock

Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) CFO Vikas Sinha sold 10,410 shares of the stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $49.57, for a total value of $516,023.70. Following the completion of the transaction, the chief financial officer owned 619,856 shares of

Apr 21, 2026 01:02 AM • defenseworld.net

Scholar Rock (NASDAQ:SRRK) Insider Akshay Vaishnaw Sells 12,246 Shares

Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) insider Akshay Vaishnaw sold 12,246 shares of Scholar Rock stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $49.57, for a total transaction of $607,034.22. Following the sale, the insider directly owned 630,542 shares of the company's stock,

Apr 21, 2026 01:02 AM • defenseworld.net

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 89,304 shares of its common stock to nine newly hired employees, consisting of inducement stock options to purchase an aggregate of 38,331 shares of common stock and inducement restricted stock units, covering an aggregate of 50,973 shares of its common stock. The awards are subject to all terms and conditions and other provisio.

Apr 17, 2026 12:15 PM • businesswire.com

Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the financial markets open. The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to “Events and Presentations” in the Investors section of the Scholar Rock website at http://investors.scholarrock.com. To participate via telephone, please reg.

Apr 16, 2026 04:00 AM • businesswire.com

SRRK Stock Jumps on Resubmission of FDA Filing for SMA Drug

Scholar Rock stock jumps 14% after it resubmits its FDA filing for SMA drug apitegromab, revives approval hopes and sets up a potential September 2026 decision.

Apr 01, 2026 09:40 AM • zacks.com

Scholar Rock Holding Corporation (SRRK) Discusses BLA Resubmission for Apitegromab in Spinal Muscular Atrophy and Regulatory Progress Transcript

Scholar Rock Holding Corporation (SRRK) Discusses BLA Resubmission for Apitegromab in Spinal Muscular Atrophy and Regulatory Progress Transcript

Mar 31, 2026 10:22 AM • seekingalpha.com

Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced it has resubmitted the Biologics License Application (BLA) for apitegromab for the treatment of children and adults with SMA to the U.S.

Mar 31, 2026 03:00 AM • businesswire.com

Scholar Rock: From Manufacturing Hurdle To Commercial Muscle, Maintaining Buy Rating

Scholar Rock (SRRK) is transitioning from regulatory uncertainty to a clear execution path for a 2026 US launch of apitegromab. Resolution of FDA manufacturing concerns at Catalant's facility and resumed operations significantly de-risk the regulatory timeline for SRRK. A $550M non-dilutive debt facility and $370M cash position strengthen SRRK's balance sheet, minimizing dilution risk.

Mar 28, 2026 06:23 AM • seekingalpha.com

E. Ohman J or Asset Management AB Has $721,000 Stake in Scholar Rock Holding Corporation $SRRK

E. Ohman J or Asset Management AB cut its position in shares of Scholar Rock Holding Corporation (NASDAQ: SRRK) by 76.6% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 16,374 shares of the company's stock after selling

Mar 26, 2026 12:07 AM • defenseworld.net

Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Rating of “Buy” from Analysts

Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) has been assigned a consensus rating of "Buy" from the seventeen ratings firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, twelve have given a buy recommendation and four have given a strong buy

Mar 22, 2026 10:22 PM • defenseworld.net

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 60,655 shares of its common stock to five newly hired employees, consisting of inducement stock options to purchase an aggregate of 24,506 shares of common stock and inducement restricted stock units, covering an aggregate of 36,149 shares of its common stock. The awards are subject to all terms and conditions and other provisio.

Mar 13, 2026 12:15 PM • businesswire.com

Scholar Rock price target raised to $55 from $53 at Barclays

$55.00 (was $46.45)

Barclays

May 08, 2026 06:35 AM • TheFly

Scholar Rock price target raised to $65 from $58 at H.C. Wainwright

$65.00 (was $46.45)

H.C. Wainwright

May 08, 2026 06:22 AM • TheFly

Scholar Rock initiated with a Buy at Canaccord

$62.00 (was $47.80)

Canaccord Genuity

Apr 20, 2026 04:21 PM • TheFly

'We are incrementally positive on Scholar Rock (SRRK) Shares'; PT Raised at Piper Sandler

$58.00 (was $44.85)

Allison Bratzel · Piper Sandler

Mar 04, 2026 07:55 AM • StreetInsider

Scholar Rock (SRRK) PT Raised to $53 at Barclays

$53.00 (was $44.31)

Etzer Darout · Barclays

Mar 03, 2026 04:01 PM • StreetInsider

Scholar Rock (SRRK) PT Raised to $55 at Truist Securities

$55.00 (was $44.31)

Srikripa Devarakonda · Truist Financial

Mar 03, 2026 01:54 PM • StreetInsider

Scholar Rock price target raised to $58 from $44 at H.C. Wainwright

$58.00 (was $44.29)

Andres Maldonado · H.C. Wainwright

Jan 26, 2026 06:16 AM • TheFly

UBS Starts Scholar Rock (SRRK) at Buy

$60.00 (was $41.31)

Michael Yee · UBS

Jan 07, 2026 01:02 AM • StreetInsider

Scholar Rock price target raised to $52 from $45 at Barclays

$52.00 (was $44.32)

Etzer Darout · Barclays

Dec 17, 2025 05:58 AM • TheFly

Scholar Rock price target raised to $50 from $45 at BMO Capital

$50.00 (was $37.41)

BMO Capital

Nov 14, 2025 12:48 PM • TheFly

Scholar Rock price target lowered to $51 from $52 at Piper Sandler

$51.00 (was $33.75)

Allison Bratzel · Piper Sandler

Sep 24, 2025 06:39 AM • TheFly

Scholar Rock price target lowered to $44 from $45 at Barclays

$44.00 (was $33.39)

Etzer Darout · Barclays

Sep 24, 2025 05:28 AM • TheFly

Scholar Rock initiated with an Overweight at Barclays

$45.00 (was $32.34)

Barclays

Sep 16, 2025 04:17 PM • TheFly

Scholar Rock assumed with a Strong Buy at Raymond James

$53.00 (was $37.27)

Raymond James

Jul 29, 2025 04:40 PM • TheFly

Scholar Rock (SRRK) PT Raised to $39 at BMO Capital

$39.00 (was $26.97)

Etzer Darout · BMO Capital

Nov 13, 2024 07:43 AM • StreetInsider

Scholar Rock (SRRK) PT Raised to $42 at Piper Sandler

$42.00 (was $28.52)

Allison Bratzel · Piper Sandler

Oct 15, 2024 03:24 AM • StreetInsider

Scholar Rock (SRRK) PT Raised to $38 at BMO Capital

$38.00 (was $25.27)

Etzer Darout · BMO Capital

Oct 11, 2024 02:58 AM • StreetInsider

Scholar Rock price target raised to $31 from $29 at BMO Capital

$31.00 (was $9.39)

Etzer Darout · BMO Capital

Jun 13, 2024 03:24 AM • TheFly

Piper Sandler Reiterates Overweight Rating on Scholar Rock (SRRK)

$28.00 (was $11.18)

Allison Bratzel · Piper Sandler

May 23, 2024 04:34 AM • StreetInsider

BMO Capital Reiterates Outperform Rating on Scholar Rock (SRRK)

$29.00 (was $11.18)

Etzer Darout · BMO Capital

May 23, 2024 03:40 AM • StreetInsider